0
(log) C-reactive protein, lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline 4 1 phosphatase, and white blood cell count) and chorological age were selected for inclusion based on ten-fold 4 2 cross-validation.
3
Two Gompertz proportional hazard models were fit. One model, h 1 (t), was fit using all ten selected variables, and the other model, h 2 (t), was fit using only chronological age. "Phenotypic Age" used for predicting t-year 4 5 mortality was calculated by asking what chronological age in h 2 (t) produced a hazard that was equal to the 4 6 hazard for h 1 (t), estimated based on the individual's observed levels of nine biomarkers and age. Thus,
7
Phenotypic Age represents the expected age within the population that corresponds to a person's estimated 4 8 mortality risk (hazard at t years). Formula were expressed as following:
Suppose we want to get phenotypic age for prediction of mortality after 1 year, with five categories-no disease, one disease, two diseases, three diseases, and four or more diseases. Age stratified ordinary least square (OLS) regression models were used to estimate the association between (Gompertz distribution) was used to assess the association between Phenotypic Age and all-mortality, with 6 6 adjustment for chronological age. To further evaluate robustness, age-stratified models and a model that
excluded short-term mortality (within five years after baseline, to ensure that Phenotypic Age was not just 6 8
capturing an end of life phenotype) were also run.
9
Next, participants were grouped into quintiles for the residual of Phenotypic Age (after regressing out 7 0 chronological age), so that the highest quintile represented individuals who were most at-risk of death for their
ages-i.e. those whose Phenotypic Age was the highest relative to their chronological age. We then plotted
Kaplan-Meier Curves for persons in the highest 20% versus the lowest 20%. We also compared predicted 7 3
median life expectancies at age 65 by sex and the five quintiles for Phenotypic Age, adjusted for age. Receiver Operating Characteristics (ROC) curves were used to compare ten-year mortality risk prediction of Phenotypic
Age to individuals' clinical chemistry measures and routine risk assessment tools.
6
Cause-specific mortality risk as a function of Phenotypic Age was assessed via Fine and Gray's 7 7
competing risk models [20] . To determine whether Phenotypic Age could differentiate risk in a healthy 7 8
population, we conducted the all-cause mortality analysis again, restricting the sample to those with no reported 7 9
disease and with normal BMI. Finally, participants aged 85+(oldest-old) were excluded from all prior analyses 8 0
given that age was top-coded; therefore, to test mortality associations in this group, we used two parametric
proportional hazard models (Gompertz distribution), one unadjusted and another with adjustment for disease 8 2 counts, rather than chronological age (unknown). 
Results

7
Prevalence of disease 8 8
The basic characteristics of the study participants are shown in Table S1 . Fig 1 presents older phenotypically than disease-free persons, and those with two or three diseases were about 0.6 years older 0 4
phenotypically. In middle aged adults, compared to those who were disease-free, those with one disease had 0 5
Phenotypic Ages that were 0.2 years older, those with two diseases had Phenotypic Ages that were 0.3 years 0 6
older, and those with three or more were on average 0.6-0.7 years older, phenotypically. Finally, for older adults,
Phenotypic Age increased consistently as a function of disease, with those reporting one disease having 0 8
Phenotypic Ages that were on average 0.1 years older than disease-free participants, those with two diseases Associations with all-cause mortality 1 4 an 8% increase in mortality risk. When examining mortality within age stratified groups, we found that 2 0
Phenotypic Age was predictive in all age groups, such that each one year increase in Phenotypic Age was 2 1 associated with a 14% increased mortality risk in young adults, 10% in middle-aged adults, and 8% in older adults. Finally, we found that on average, females were phenotypically younger than males (β=-1.34, P<2.2E-2 3 16); therefore, we compared sex-stratified model of all-cause mortality associations and found identical results
4
for both sexes (females: HR=1.09, 95%CI=1.07-1.11; males: HR=1.09, 95%CI=1.07-1.11).
5
As shown in Fig 4, we found that those with the highest Phenotypic Ages, relative to their chronological 2 6
ages had much steeper declines in survival over the approximately 12.5 years of follow-up. Interestingly, the 2 7
high-risk groups appeared to have mortality rate that were similar, or in some cases higher than persons in the 2 8
lowest risk group who were ten years older chronologically. For instance, among persons aged 50-64 y at 2 9
baseline, about 25% of the high risk group had died after ten years of follow-up. Conversely among persons aged 65-74 y in the high risk group about half had died after ten years, compared to only about 67% of the low 3 2
risk group who aged 75-85 y. Age. Results showed that 65-year-old females in the healthiest quintile had a predicted median life expectancy
of about 87 y, while females in the unhealthiest quintile had a predicted life expectancy of just over 78 y.
6
Similarly, 65-year-old males in the healthiest quintile had a predicted median life expectancy of about 84.5 y,
while males in the unhealthiest quintile had a predictive life expectancy of just under 76 y. Associations with disease-specific mortality 
